PGC1A is also negatively regulated by TRPV4, while TRPV4 antagonists reduce high‐fat diet‐induced obesity, insulin resistance, diabetic nephropathy, retinopathy, and neuropathy. Here, PPARGC1A is linked to retinal disorder.